Antonio Wolff named co-lead of NCI Breast Cancer Steering Committee

On Capitol Hill, NIH gets congressional support and RFK Jr. gets slammed

As NIH and NCI funding is negotiated in Congress, Paul W. Thurman felt compelled to crunch some numbers. He compared the U.S.’s cumulative funding for NCI to the funding slated for ICE—the latter of which vastly outweighs the former—and asked whether the funding priorities of the federal government are properly representing the nation’s mortality.

September 10, 2025

Vol.51 No.32

Capitol Hill

House committee’s FY26 spending bill increases NCI funding by $48M, NIH by $99M
House joins Senate in rejecting Trump’s proposed 40% NIH cuts

The House is on track to join the Senate in rejecting the Trump administration’s budget proposal that would cut NIH by $18 billion.

September 05, 2025

Vol.51 No.32

By Jacquelyn Cobb and Paul Goldberg

Guest Editorial

Curing cancer or curbing immigration: A question of national morality and priority

In December 1971, President Richard Nixon signed the National Cancer Act and declared a “War on Cancer.” In the past 54 years, the U.S. has invested $180 billion nominally, or approximately $322 billion when adjusted for inflation, in cancer research. This investment has paid dividends with more than 100 anticancer drugs brought to market in half a century—virtually all traceable to National Cancer Institute funding.

Julie Bauman named deputy chair of NRG Oncology’s NCORP research program, Ryan Burri named vice chair of Veteran Affairs research

Julie BaumanRyan BurriNRG Oncology, an NCI National Clinical Trials Network group focused on multi-center clinical research, appointed Julie Bauman as deputy chair of the Community Oncology Research Program.

September 05, 2025

Vol.51 No.32

Clinical Roundup

MammaPrint predicts chemotherapy benefit in HR+HER2 early breast cancer patients, observational FLEX study finds

The MammaPrint, a gene expression profiling test, predicts the benefit of chemotherapy for patients with hormone receptor-positive, HER2-negative early-stage breast cancer, according to findings published in JNCI Cancer Spectrum.

September 05, 2025

Vol.51 No.32

Cancer Policy

ACOG says it will no longer accept federal funding

The American College of Obstetrics and Gynecology said it will no longer be accepting federal funding.

August 08, 2025

Vol.51 No.31

By Claire Marie Porter

Antonio Wolff named co-lead of NCI Breast Cancer Steering Committee

YOU MAY BE INTERESTED IN

On Capitol Hill, NIH gets congressional support and RFK Jr. gets slammed

House committee’s FY26 spending bill increases NCI funding by $48M, NIH by $99M
House joins Senate in rejecting Trump’s proposed 40% NIH cuts

Curing cancer or curbing immigration: A question of national morality and priority

Julie Bauman named deputy chair of NRG Oncology’s NCORP research program, Ryan Burri named vice chair of Veteran Affairs research

MammaPrint predicts chemotherapy benefit in HR+HER2 early breast cancer patients, observational FLEX study finds

ACOG says it will no longer accept federal funding

Renew today!

Subscriber content

Never miss an issue!

Login

Antonio Wolff named co-lead of NCI Breast Cancer Steering Committee

YOU MAY BE INTERESTED IN

On Capitol Hill, NIH gets congressional support and RFK Jr. gets slammed

House committee’s FY26 spending bill increases NCI funding by $48M, NIH by $99MHouse joins Senate in rejecting Trump’s proposed 40% NIH cuts

Curing cancer or curbing immigration: A question of national morality and priority

Julie Bauman named deputy chair of NRG Oncology’s NCORP research program, Ryan Burri named vice chair of Veteran Affairs research

MammaPrint predicts chemotherapy benefit in HR+HER2 early breast cancer patients, observational FLEX study finds

ACOG says it will no longer accept federal funding

Never miss an issue!

Login

House committee’s FY26 spending bill increases NCI funding by $48M, NIH by $99M
House joins Senate in rejecting Trump’s proposed 40% NIH cuts